Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1033–1044 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187
Site status not listed — check the official record
Conditions
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide (TMZ)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 39 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

NCT07273838
Status at this site: Recruiting
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Recruiting No phase listed Observational

Terumo Aortic Global Endovascular Registry

NCT04246463
Status at this site: Recruiting
Conditions
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Interventions
Thoracic, Abdominal, Custom Device, Illiac Artery
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
17
States / cities
Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Not yet recruiting Not applicable Interventional

Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

NCT06596512
Site status not listed — check the official record
Conditions
Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
Interventions
PARTICS using a single ICS add on, MART
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
4,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

SV2A Density Cannabis Use Disorder

NCT05472818
Status at this site: Recruiting
Conditions
Cannabis Use Disorder, Healthy
Interventions
[11C]APP311
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents

NCT07460622
Site status not listed — check the official record
Conditions
E-cigarette Use/Vaping Prevention, Nicotine Dependence Prevention, Adolescent Mental Health
Interventions
Virtual Reality E-Cigarette Prevention Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 15 Years
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 2 Interventional Accepts healthy volunteers

Imaging Depression in Parkinson's Disease

NCT06402955
Status at this site: Recruiting
Conditions
Parkinson's Disease, Major Depressive Disorder
Interventions
11C-UCB-J, ketamine hydrochloride
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189
Site status not listed — check the official record
Conditions
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Interventions
Pembrolizumab, Paclitaxel, Bevacizumab, Placebo for pembrolizumab, Docetaxel
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Greenbrae, California • Monterey, California + 28 more
Active, not recruiting Phase 2 Interventional

Abemaciclib and Letrozole to Treat Endometrial Cancer

NCT04393285
Site status not listed — check the official record
Conditions
Endometrial Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more
Recruiting No phase listed Observational

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

NCT07155252
Status at this site: Recruiting
Conditions
Type 1 Diabetes
Interventions
GTT@Home
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
8 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

NCT06028932
Site status not listed — check the official record
Conditions
Ovarian Carcinoma
Interventions
Sacituzumab govitecan
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lung Carcinoma
Interventions
Educational Intervention, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
16
States / cities
Davis, California • Duarte, California • Irvine, California + 13 more

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.